La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological malignancies and solid tumors
--- Three preclinical poster presentations highlight the potential of RP4010 alone and in combination with approved drugs for treating hematological malignancies and solid tumors
--- A multi-center Phase I/IB dose-escalation trial evaluating the safety and efficacy of RP4010, a CRAC channel inhibitor in patients with relapsed or refractory Non-Hodgkin Lymphoma (NHL) is currently ongoing in USA (ClinicalTrials.gov Identifier: NCT03119467)
About RP4010:
RP4010 is a novel first-in-class oral small molecule inhibitor of calcium release activated calcium (CRAC) channel pathway with demonstrated preclinical activity in a broad range of cancers. Aberrant CRAC channel activity has been linked to various autoimmune disorders and certain cancers via the NFAT pathway. In addition, the blockage of store-operated calcium entry (SOCE) by a CRAC channel inhibitor could suppress tumor growth through a number of mechanisms, including the inhibition of calcium-dependent activation of Akt/NF-kB and ERK 1/2 pathways.
Details of the poster presentations:
-- Poster Title: Antitumor activity of RP4010, a novel small-molecule inhibitor of the calcium release-activated calcium (CRAC) channel pathway
- Session Title: Poster Session B
- Session Category: Therapeutic Agents: Other Topics
- Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
- Location: Hall E, Pennsylvania Convention Center
- Poster Board Number: 127
-- Poster Title: Efficacy of RP4010, a calcium release-activated calcium (CRAC) inhibitor, in preclinical models of DLBCL
- Session Title: Poster Session B
- Session Category: Therapeutic Agents: Other Topics
- Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
- Location: Hall E, Pennsylvania Convention Center
- Poster Board Number: 128
-- Poster Title: Targeting Orai1-mediated store-operated Ca2+ entry by a novel compound RP4010 for antiproliferative activity against Esophagus Squamous Cell Carcinoma
- Session Title: Poster Session B
- Session Category: New Molecular Targets
- Session Date & Time: Sunday, October 29, 2017; 12:30 PM – 4:00 PM
- Location: Hall E, Pennsylvania Convention Center
- Poster Board Number: 62
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
Contact: Kumar V. Penmetsa, Ph.D. Executive Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: kvp@rhizen.com
